Advanced Medical Isotope Corporation (OTCMKTS:RDGL) Sees Significant Decrease in Short Interest

Advanced Medical Isotope Corporation (OTCMKTS:RDGL) was the recipient of a significant decline in short interest in August. As of August 31st, there was short interest totaling 10,391 shares, a decline of 87.4% from the August 15th total of 82,653 shares. Based on an average daily volume of 1,483,590 shares, the short-interest ratio is currently 0.0 days. Approximately 0.0% of the company’s stock are short sold.

Advanced Medical Isotope Trading Up 2.5%

Shares of OTCMKTS:RDGL opened at $0.05 on Friday. Advanced Medical Isotope has a 1 year low of $0.04 and a 1 year high of $0.12. The business has a fifty day simple moving average of $0.06 and a 200 day simple moving average of $0.07. The firm has a market cap of $24.50 million, a price-to-earnings ratio of -4.96 and a beta of -0.72.

Advanced Medical Isotope Company Profile

Vivos Inc, a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc in December 2017. Vivos Inc was incorporated in 1994 and is headquartered in Richland, Washington.